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Abstract: The aim of this study was to evaluate complications of surgical intervention for participants
in the Kentucky Ovarian Cancer Screening Program and compare results to those of the Prostate,
Lung, Colorectal and Ovarian Cancer Screening trial. A retrospective database review included
657 patients who underwent surgery for a positive screen in the Kentucky Ovarian Cancer Screening
Program from 1988–2014. Data were abstracted from operative reports, discharge summaries, and
office notes for 406 patients. Another 142 patients with incomplete records were interviewed by
phone. Complete information was available for 548 patients. Complications were graded using the
Clavien–Dindo (C–D) Classification of Surgical Complications and considered minor if assigned
Grade I (any deviation from normal course, minor medications) or Grade II (other pharmacological
treatment, blood transfusion). C–D Grade III complications (those requiring surgical, endoscopic,
or radiologic intervention) and C–D Grade IV complications (those which are life threatening) were
considered “major”. Statistical analysis was performed using SAS 9.4 software. Complications were
documented in 54/548 (10%) subjects. For women with malignancy, 17/90 (19%) had complications
compared to 37/458 (8%) with benign pathology (p < 0.003). For non-cancer surgery, obesity was
associated with increased complications (p = 0.0028). Fifty patients had minor complications classified
as C–D Grade II or less. Three of 4 patients with Grade IV complications had malignancy (p < 0.0004).
In the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial, 212 women had surgery for
ovarian malignancy, and 95 had at least one complication (45%). Of the 1080 women with non-cancer
surgery, 163 had at least one complication (15%). Compared to the Prostate, Lung, Colorectal and
Ovarian Cancer Screening trial, the Kentucky Ovarian Cancer Screening Program had significantly
fewer complications from both cancer and non-cancer surgery (p < 0.0001 and p = 0.002, respectively).
Complications resulting from surgery performed as a result of the Kentucky Ovarian Cancer Screening
Program were infrequent and significantly fewer than reported in the Prostate, Lung, Colorectal and
Ovarian Cancer Screening trial. Complications were mostly minor (93%) and were more common in
cancer versus non-cancer surgery.
Keywords: ovarian cancer screening; complications; ovary; cancer; screening
1. Introduction
Ovarian cancer is the most common cause of gynecologic cancer death in the United States with
22,280 new cases and 14,240 deaths from the disease in 2016 [1]. Despite the introduction of targeted
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therapies, refinements in novel chemotherapy regimens, and advances in surgical techniques, survival
outcomes have remained essentially unchanged over time [2]. Most patients with ovarian cancer are
diagnosed with advanced stage disease where survival outcomes are poor. Surgical stage at the time
of diagnosis remains among the most important prognostic factors for patients with ovarian cancer.
Women with Stage I disease, where cancer is confined to one or both ovaries have a 10-year survival
rate of 74%, whereas those with Stages II, III, and IV disease have 10-year survival rates of 45%, 21%,
and <5%, respectively [3]. Identifying women with early stage disease is difficult since early ovarian
cancer does not reliably cause symptoms. A specific symptom profile has been described in patients
with ovarian cancer; however, it is most often reported in those with advanced stage disease [4].
Early stage disease rarely demonstrates this symptom profile [5,6].
The key to a successful screening program is the increased detection of early stage disease and
subsequent improved survival in the screen-detected cancers. Efforts in ovarian cancer screening
have focused on the integration of transvaginal sonography and serum biomarkers, specifically CA
125 [7–10]. Improved survival from ovarian cancer screening has been reported [11–13], especially
with regard to screen-detected incident ovarian cancers [9,14]. One large trial (the Prostate, Lung,
Colorectal and Ovarian (PLCO) Randomized Controlled Screening Trial: PLCO trial) failed to observe
improved survival in the intervention (screening) group [15] and reported a surprisingly high false
positive rate with 19 women recommended for surgery for every malignancy that was identified [16].
This is in contrast to other screening studies that reported lower false positive rates [9,11,13]. In the
PLCO trial, screen positive cases found to be non-malignant at surgery had an unexpectedly high
complication rate (15%) [15] and led to announcements that ovarian cancer screening does more harm
than good [17]. In comparison, the United Kingdom Controlled Trial on Ovarian Cancer Screening
(UKCTOCS trial) reported a surgical complication rate of less than 1% [9].
The present study examines complications in women undergoing surgery as a result of an
abnormality detected in the Kentucky Ovarian Cancer Screening Program, an ultrasound-based
program that has screened over 40,000 women from 1988 to present. We objectively evaluated
the number and type of complications observed in these women using the Clavien–Dindo (C–D)
Classification of Surgical Complications [18,19] and compared findings to those reported in the
PLCO trial.
2. Methods
The study was approved by the (University of Kentucky Institutional Review Board protocol
88-0021-9F with the most recent renewal on 11 August 2016. Women enrolled in the Kentucky
Ovarian Cancer Screening Program from 26 May 1988 to 1 June 2014 were included in the study group
(n = 41,529). The University of Kentucky Institutional Review Board approved this study. Women
were recruited by physician referral, media announcements, and word of mouth. Eligibility criteria
included asymptomatic women age 50 years or older without a family history of ovarian cancer,
or those 25 years or older with a documented family history of ovarian cancer in at least one first
or second-degree relative, and the ability to read and understand the informed consent presented
in English. Women under clinical evaluation because of pelvic symptoms, a known ovarian tumor,
or a personal history of ovarian cancer were excluded. Women enrolled in the Kentucky Ovarian
Cancer Screening Program underwent annual screening with transvaginal sonography. Abnormalities
were managed according to the study algorithm (Figure 1), which included increased frequency of
screening with transvaginal sonography, assessment of morphology index score, and serum CA 125
(Figure 2). Diagnostic surgical intervention was recommended if results indicated at least moderate
risk of malignancy according to the published protocol [20]. Minimally invasive surgical technique was
preferred, unless medical issues prohibited this approach. Details of the study algorithm, threshold for
intervention, and cancer outcomes have been previously published [12,20].
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in these 548 patients according to the C–D Classification of Surgical Complications (Table 1) [18,19].
Complications were considered “minor” if they were C–D Grades I or II. Grade I complications
included any minor deviations from a normal postoperative course without the need for pharmacologic
intervention. Grade II complications consisted of complications treated pharmacologically. C–D Grade
III complications (those requiring surgical, endoscopic, or radiologic intervention) and C–D Grade IV
complications (those which are life threatening) were considered “major.”
Table 1. Classification of Surgical Complications. Modified from [19].
C–D Grades Definition
Grade I
Any deviation from normal postoperative course without the need for pharmacological
treatment or surgical, endoscopic and radiological interventions. Acceptable
therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics, and
electrolytes and physiotherapy.
Grade II Requiring pharmacological treatment with drugs other thanthan such allowed forGrade I complications.
Grade III Requiring surgical, endoscopic or radiologic intervention.
Grade III-a Intervention not under general anesthesia.
Grade III-b Intervention under general anesthesia.
Grade IV Life threatening complications (including CNS complications)
‡ requiring
IC/ICU management.
Grade IV-a Single organ dysfunction (including dialysis).
Grade IV-b Multi organ dysfunction.
Grade V Death of patient.
Suffix “d”
If the patient suffers from a complication at the time of discharge (see examples in
Appendix B, http://Links.Lww.com/SLA/A3), the suffix “d” (for “disability”) is
added to the respective grade of complication. This label indicates the need for a
follow-up to fully evaluate the complication.
‡ Brain hemorrhage, ischemic stroke, subarachnoid bleeding, but excluding transient ischemic attacks (TIA);
IC: intermediate care; ICU: intensive care unit (www.surgicalcomplications.info).
Descriptive analysis for demographics and clinical factors was performed. We used χ2 tests to
examine associations between complication status (yes and no) and other factors such as age, race, body
mass index (BMI), type of surgery, cancer status, and type of hospital where surgery was performed.
Multivariate logistic regressions were fitted to evaluate the association between complication status and
other factors. The final model included only covariates with a significance level of 0.05 or less. Model
goodness of fit, multicollinearity, and interactions were also examined. All analyses were performed
using SAS Statistical software version 9.4. All statistical tests were two-sided with a p-value ≤0.05
used to identify statistical significance.
3. Results
Complete clinical information was available on 548 of the 657 patients who underwent surgery for
positive screens in the Kentucky Ovarian Cancer Screening Program between the years of 1988–2014.
A summary of demographic information is presented in Table 2 and shows that women with and
without complications were similar. Complications were documented in 54 of 548 (10%) subjects.
Fifty patients (93%) had minor complications classified as C–D Grade II or less, while four had
complications categorized as C–D Grade IV. Complication profiles for individuals are shown relative
to age and BMI in Figure 3.
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Variable No Complications Complications Excluded
N = 494 N = 54 N = 109
Age 59.7, 59 (29–86) 59.6, 59 (38–79) 59.6, 60 (36–84)
Weight 163.6, 158.5 (80–368) 173.7, 170 (121–274) 159.2, 150 (101–250)
Height 64. , 64.5 (5 –71) 64.4, 65 ( 0–70) 64.5, 64 (57–72)
BMI 27.6, 26.6 (15.1–58.4) 29.4, 29.2 (19.9–45.7) 26.9, 25.8 (18–43.9)
Family history of:
Ovarian cancer 132 (26.7%) 15 (27.8%) 36 (33%)
Breast cancer 27 (50%) 217 (43.9%) 46 (42.2%)
Breast cancer personal history 8 (14.8%) 39 (7.9%) 8 (7.3%)
Colon cancer 128 (25.9%) 11 (20.3%) 46 (24.7%)
Colon cancer personal history 3 (0.6%) 0 (0%) 1 (0.9%)
No history of hormone
replacement therapy 372 (75.3%) 43 (79.6%) 65 (59.6%)
History of hormone
replacem nt therapy 122 (24.7%) 11 (20.4%) 38 (34.9%)
Menopausal Status
Premenopausal 73 (14.8%) 6 (11.1%) 18 (16.5%)
Perimenopausal 18 (3.6%) 0 7 (6.4%)
Postmenopausal 403 (81.6%) 48 (88.9%) 84 (77.1%)
Any symptoms 254 (51%) 30 (55.5%) 51 (46.8%)
Ovarian cancer symptoms * 27 (14.8%) 4 (7.4%) 5 (4.6%)
Other symptoms ** 248 (50.2%) 30 (55.6% 48 (44%)
Mean, median (range) * Women reporting pelvic or abdominal pain, being unable to eat normally, feeling full quickly,
feeling abdominal bloating or increased abdominal size presenting for >12 days per month with an onset in less
than the last 12 months. ** Women reporting back pain, indigestion, nausea, vomiting, weight loss, urinary urgency,
frequent urination, constipation, menstrual irregularities, bleeding after menopause, pain during intercourse,
fatigue, leg swelling, difficulty breathing. Any symptoms: any symptom included under ovarian cancer symptoms
or other symptoms without regard to frequency of duration.
Complication rates were c mpa ed for surgeries that res lted in the diagnosis of malignancy
versus surgery for false positive screens with benign pathology. For wom n with mali nancy, 17 of 90
(19%) h d complications co pared to 37 of 458 (8%) with benign pathology (p < 0.003), Figure 4. Thus,
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a diagnosis of cancer increased the likelihood of complications with an odds ratio of 2.65. Three of four
patients with C–D Grade IV complications had malignancy, while one Grade IV complications occurred
in the benign conditions group (p < 0.0004). In the PLCO trial, 212 women in the intervention group
had surgery for ovarian malignancy, and 95 had at least one complication (45%). Of the 1080 women
with surgery with a benign outcome, 163 had at least one complication (15%), yielding an odds ratio of
3 for complications in surgical cancer cases over benign surgical cases. Complication rates from the
Kentucky Ovarian Cancer Screening Program were compared with the PLCO trial results. Compared to
the PLCO trial, the Kentucky Ovarian Cancer Screening Program had significantly fewer complications
from both cancer (p < 0.001) and non-cancer surgery (p = 0.002) based on chi-square analysis (Figure 4).
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Bivariate analysis of complication status versus other clinical variables was performed and obesity
was associated with increased incidence of complication, p = 0.049 (Table 3). Evaluating clinical
variables by cancer status, obesity was not associated with increased complications in surgeries
performed for non-cancer pathology, p = 0.458 (Table 4). While patients with a cancer diagnosis were
significantly older than those with a benign diagnosis, p = 0.002 (Table 4), age was not different for
those who had complications when compared to those that did not, p = 0.463 (Table 3). Other factors
evaluated in bivariate analysis did not show significant differences based on complication status.
Table 3. Associations between complications and other factors.
Variables
Complications No Complications
p-Value
N % N %
Age 0.463
<50 7 13.0 75 15.2
50–64 32 59.3 257 52.0
65–74 10 18.5 121 24.5
75+ 3 5.6 35 7.1
Unknown 2 3.7 6 1.2
Weight 0.049
Under-weight 0 0.0 5 1.0
Normal 11 20.4 185 37.4
Over-weight 20 37.0 175 35.4
Obese 20 37.0 108 21.9
Extreme obesity 3 5.6 21 4.3
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Table 4. Patient characteristics by cancer status.
Variables
Cancer Non-Cancer
p-Value
N % N %
Age 0.002
<50 6 6.7 76 16.6
50–64 38 42.2 251 54.8
65–74 33 36.7 98 21.4
75+ 11 12.2 27 5.9
Unknown 2 2.2 6 1.3
C–D Grade N % N % <0.001
None 73 81.1 421 92.0
Minor 14 15.6 36 7.9
Severe 3 3.3 1 0.2
Weight 0.458
Under-weight 1 1.1 4 0.9
Normal 37 41.1 159 34.7
Over-weight 31 34.4 164 35.8
Obese 20 22.2 108 23.6
Extreme obesity 1 1.1 23 5.0
In multivariate analysis, obesity was determined to be associated with increased risk of
complication versus normal weight (OR 3.17, 1.46–6.90). The location where the procedures were
performed was also significantly associated with complication risk (OR 1.97, 1.07–3.65) (Table 5).
Table 5. Odds ratio estimates.
Effect Odds Ratio 95% Confidence Limits
Age
Unknown vs. 50–64 4.75 (0.86–26.19)
<50 vs. 50–64 0.76 (0.32–1.81)
75+ vs. 50–64 0.77 (0.22–2.71)
65–74 vs. 50–64 0.69 (0.33–1.48)
Weight
Overweight vs.
Underweight/Normal 2.06 (0.95–4.49)
Obese vs.
Underweight/Normal 3.17 (1.46–6.90)
Location
UK vs. Non-UK 1.97 (1.07–3.65)
4. Discussion
Ovarian cancer is the second most common gynecologic cancer, but the most common cause
of gynecologic cancer death. Most women have advanced disease at the time of their diagnosis,
with cancer spread throughout the peritoneal cavity and occasionally into the pleural cavity. Despite
aggressive surgery and chemotherapy [21], the five-year overall survival for patients with advanced
ovarian cancer is less than 30%. Unfortunately, only about 25% of women present with early stage
ovarian cancer, where the five-year overall survival may exceed 80%–90% with appropriate surgical
staging and adjuvant therapy.
Ovarian cancer screening with transvaginal sonography and serum biomarkers has been explored
as a means for increasing the number of women diagnosed with early stage disease [7–13,20]. This shift
in stage at diagnosis should result in an improved overall survival as a result of screening. There is
a need for ovarian cancer screening because early stage disease rarely produces reliable symptoms.
Goff and colleagues reported a symptom profile associated with ovarian cancer [4,22], which included
abdominal pain or bloating, pelvic pain, and urinary symptoms present for more than two weeks
out of the month and persisting for fewer than 12 months. The effectiveness of a symptom profile is
limited as a screening tool because the profile is most useful for identifying advanced stage disease.
Ovarian cancer screening presents unique challenges that are inherent to the disease itself. First,
ovarian cancer has a low incidence with only 22,280 new cases expected in 2016, compared to breast or
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colorectal cancer in women with 246,660 and 68,830 new cases, respectively [1]. The annual balance of
deaths from disease to incident cases for ovarian cancer (0.639) is 3.9 times higher than for breast (0.164)
and 1.8 times higher than for colorectal cancer (0.346), indicating that ovarian cancer is a much deadlier
disease. This is reflected in the low prevalence of ovarian cancer with an estimated 195,767 women
living with the disease in the United States in 2013, relative to colorectal (1,177,556) and breast cancers
(3,053,450) [23].
A second challenge in ovarian cancer screening is the lack of a thorough understanding of the
etiology and natural history of ovarian, primary peritoneal, and fallopian tube cancer. Historically,
ovarian cancer was thought to arise from the surface epithelium of the ovary. However, this did
not explain normal size ovaries as seen in primary peritoneal cancers. The similarities between
serous ovarian and primary peritoneal cancers from the standpoint of genetic mutations, histology,
behavior, and response to treatment suggest similar etiologic factors. More recently, investigators
have hypothesized that ovarian, primary peritoneal, and fallopian tube cancers originate from
serous intraepithelial carcinomas in the fallopian tube [24–33]. If this is the case, then screening
for abnormalities of the ovary with transvaginal sonography will prove futile because the early
abnormalities exist in the fallopian tube. This model is founded on the presence of microscopic disease
that is below the resolution of biomarkers and ultrasonography, and consequently implies that these
screening tools cannot be effective. However, the discovery of Stage I cancers in several screening
studies indicates that biomarker and ultrasonography screening modalities are sufficiently effective
in detecting ovarian cancer early enough to decrease mortality and increase survival [9–12]. Thus,
cases that have progressed beyond microscopic disease in the distal fallopian tube can be detected
by biomarker and ultrasonography screening often enough to achieve a favorable prognosis for
extending survival.
In the present report, we evaluate the complications related to surgery for a positive ovarian
cancer screen. In other cancers, such as breast, colon, and cervical, a diagnostic biopsy is performed
to determine the presence or absence of malignancy. Percutaneous or transvaginal biopsy of ovarian
abnormalities is not recommended because of concern for “seeding” the needle track in the case of
malignancy, or for rupturing a malignant tumor, resulting in potentially worse outcomes. Given
the aggressive nature of ovarian cancer, these two possibilities could impact the need for adjuvant
treatment, or increase the risk of recurrence in early stage disease. As a result, patients with a positive
screen indicating a moderate to high risk of malignancy are offered definitive surgery for diagnosis.
In most cases, removal of an ovary or ovaries because of an abnormality detected on ovarian cancer
screening can be accomplished using a minimally invasive technique, but there are situations when this
is not medically recommended. Surgical exploration for a positive screen introduces the possibility of
intervention for benign or false positive ovarian abnormalities. The combination of a high percentage
of surgeries for women without a malignancy in the PLCO trial (1 malignancy for every 19 surgeries)
coupled with a high complication rate [15] led to published statements that screening is harmful [17].
In conclusion, little has been published regarding the nature of the complications reported from
surgeries resulting from ovarian cancer screening. In this investigation, we report a low complication
rate, with 93% classified as minor. Similarly, the UKCTOCS trial reported a very low complication
rate of less than one percent in both screening groups [9]. The procedures of the PLCO trial were
to notify the referring physician that a screen was abnormal, but not to make recommendations on
whether surgery should be performed or by whom. It is possible that the high complication rates
reported in the PLCO trial [15] are related to the recent recognition that better outcomes are achieved
when ovarian cancer is treated by specialists at high volume hospitals [34–39], and this benefit may
particularly apply to early stage ovarian cancers [40]. Ultimately, the methods used to decide who
went to surgery and who would perform the operation may best explain the high false positive rates
and high complication rates observed in the PLCO trial.
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